SYNTHETIC BIOLOG.DL -,001
SYNTHETIC BIOLOG.DL -,001
Share · US87164U4094 · TOVX (LSSI)
Overview Financial Indicators
0,42 EUR
2,17 % 0,009 EUR
Lang & Schwarz (XNYS) · Current prices and charts at MoneyPeak
09.06.2025 19:55

Current Prices from SYNTHETIC BIOLOG.DL -,001

ExchangeTickerCurrencyLast TradePriceDaily Change
XNYS: NYSE
NYSE
TOVX
USD
09.06.2025 19:55
0,48 USD
0,46 USD
+4,12 %

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
1,99 % -21,55 % -28,35 % -66,55 % -64,80 % -93,11 % -99,56 %

Company Profile for SYNTHETIC BIOLOG.DL -,001 Share

Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company was formerly known as Synthetic Biologics, Inc. and changed its name to Theriva Biologics Inc. in October 2022. Theriva Biologics Inc. is headquartered in Rockville, Maryland.

Company Data

Name SYNTHETIC BIOLOG.DL -,001
Company Theriva Biologics, Inc.
Symbol TOVX
Website https://therivabio.com
Primary Exchange LSSI Lang & Schwarz
ISIN US87164U4094
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Mr. Steven A. Shallcross CPA
Country United States of America
Currency EUR
Employees 0,0 T
Address 9605 Medical Center Drive, 20850 Rockville
IPO Date 2006-12-18

Stock Splits

Date Split
26.08.2024 1:25

ID Changes

Date From To
13.10.2022 SYN TOVX
17.02.2012 AEN SYN

Ticker Symbols

Name Symbol
Frankfurt SFY.F
NYSE TOVX

More Shares

Investors who SYNTHETIC BIOLOG.DL -,001 hold also have the following shares in their portfolio:
LUZ.KANT.BK 19/42
LUZ.KANT.BK 19/42 Bond
M.A.-STOX.CH.A.MI.V.I.CEO
M.A.-STOX.CH.A.MI.V.I.CEO ETF
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025